|
Gene: EIF3A |
Gene summary for EIF3A |
Gene summary. |
Gene information | Species | Human | Gene symbol | EIF3A | Gene ID | 8661 |
Gene name | eukaryotic translation initiation factor 3 subunit A | |
Gene Alias | EIF3 | |
Cytomap | 10q26.11 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q14152 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8661 | EIF3A | HTA11_3410_2000001011 | Human | Colorectum | AD | 6.74e-07 | -4.30e-01 | 0.0155 |
8661 | EIF3A | HTA11_347_2000001011 | Human | Colorectum | AD | 1.43e-15 | 7.28e-01 | -0.1954 |
8661 | EIF3A | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.24e-04 | 6.57e-01 | -0.059 |
8661 | EIF3A | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.13e-08 | 5.29e-01 | 0.0674 |
8661 | EIF3A | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 5.13e-14 | 1.48e+00 | 0.3487 |
8661 | EIF3A | HTA11_99999965104_69814 | Human | Colorectum | MSS | 7.29e-15 | 9.98e-01 | 0.281 |
8661 | EIF3A | A002-C-010 | Human | Colorectum | FAP | 4.17e-02 | -1.48e-01 | 0.242 |
8661 | EIF3A | A015-C-203 | Human | Colorectum | FAP | 8.86e-23 | -2.25e-01 | -0.1294 |
8661 | EIF3A | A015-C-204 | Human | Colorectum | FAP | 6.32e-04 | -1.73e-01 | -0.0228 |
8661 | EIF3A | A014-C-040 | Human | Colorectum | FAP | 3.17e-03 | -3.37e-01 | -0.1184 |
8661 | EIF3A | A002-C-201 | Human | Colorectum | FAP | 2.15e-10 | -2.57e-01 | 0.0324 |
8661 | EIF3A | A001-C-119 | Human | Colorectum | FAP | 2.87e-12 | 4.78e-01 | -0.1557 |
8661 | EIF3A | A001-C-108 | Human | Colorectum | FAP | 5.01e-13 | 7.96e-02 | -0.0272 |
8661 | EIF3A | A002-C-205 | Human | Colorectum | FAP | 5.94e-20 | 1.64e-01 | -0.1236 |
8661 | EIF3A | A001-C-104 | Human | Colorectum | FAP | 7.99e-05 | 1.86e-01 | 0.0184 |
8661 | EIF3A | A015-C-006 | Human | Colorectum | FAP | 8.41e-19 | 3.28e-01 | -0.0994 |
8661 | EIF3A | A015-C-106 | Human | Colorectum | FAP | 5.10e-06 | -4.34e-02 | -0.0511 |
8661 | EIF3A | A002-C-114 | Human | Colorectum | FAP | 3.57e-16 | 5.50e-02 | -0.1561 |
8661 | EIF3A | A015-C-104 | Human | Colorectum | FAP | 2.54e-32 | 7.17e-02 | -0.1899 |
8661 | EIF3A | A001-C-014 | Human | Colorectum | FAP | 7.96e-08 | -8.77e-02 | 0.0135 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0002181 | Colorectum | AD | cytoplasmic translation | 109/3918 | 148/18723 | 3.40e-43 | 2.13e-39 | 109 |
GO:0016032 | Colorectum | AD | viral process | 168/3918 | 415/18723 | 4.67e-20 | 3.66e-17 | 168 |
GO:0022618 | Colorectum | AD | ribonucleoprotein complex assembly | 92/3918 | 220/18723 | 1.49e-12 | 2.60e-10 | 92 |
GO:0071826 | Colorectum | AD | ribonucleoprotein complex subunit organization | 94/3918 | 227/18723 | 1.70e-12 | 2.87e-10 | 94 |
GO:0022613 | Colorectum | AD | ribonucleoprotein complex biogenesis | 151/3918 | 463/18723 | 1.96e-09 | 1.39e-07 | 151 |
GO:0019080 | Colorectum | AD | viral gene expression | 42/3918 | 94/18723 | 1.90e-07 | 8.02e-06 | 42 |
GO:0002183 | Colorectum | AD | cytoplasmic translational initiation | 21/3918 | 34/18723 | 2.73e-07 | 1.09e-05 | 21 |
GO:0001732 | Colorectum | AD | formation of cytoplasmic translation initiation complex | 13/3918 | 16/18723 | 4.27e-07 | 1.64e-05 | 13 |
GO:0006413 | Colorectum | AD | translational initiation | 45/3918 | 118/18723 | 1.35e-05 | 2.92e-04 | 45 |
GO:0075522 | Colorectum | AD | IRES-dependent viral translational initiation | 8/3918 | 11/18723 | 3.26e-04 | 3.85e-03 | 8 |
GO:0019081 | Colorectum | AD | viral translation | 10/3918 | 16/18723 | 3.64e-04 | 4.22e-03 | 10 |
GO:0043409 | Colorectum | AD | negative regulation of MAPK cascade | 57/3918 | 180/18723 | 4.61e-04 | 5.14e-03 | 57 |
GO:00021812 | Colorectum | MSS | cytoplasmic translation | 108/3467 | 148/18723 | 1.78e-47 | 1.11e-43 | 108 |
GO:00160322 | Colorectum | MSS | viral process | 157/3467 | 415/18723 | 7.94e-21 | 6.19e-18 | 157 |
GO:00718262 | Colorectum | MSS | ribonucleoprotein complex subunit organization | 90/3467 | 227/18723 | 6.88e-14 | 1.78e-11 | 90 |
GO:00226182 | Colorectum | MSS | ribonucleoprotein complex assembly | 88/3467 | 220/18723 | 7.12e-14 | 1.78e-11 | 88 |
GO:00226132 | Colorectum | MSS | ribonucleoprotein complex biogenesis | 144/3467 | 463/18723 | 2.76e-11 | 3.67e-09 | 144 |
GO:00190802 | Colorectum | MSS | viral gene expression | 41/3467 | 94/18723 | 1.74e-08 | 9.85e-07 | 41 |
GO:00021832 | Colorectum | MSS | cytoplasmic translational initiation | 21/3467 | 34/18723 | 2.99e-08 | 1.67e-06 | 21 |
GO:00017322 | Colorectum | MSS | formation of cytoplasmic translation initiation complex | 13/3467 | 16/18723 | 9.42e-08 | 4.63e-06 | 13 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EIF3A | SNV | Missense_Mutation | c.2393N>A | p.Arg798His | p.R798H | Q14152 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-BR-8363-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
EIF3A | SNV | Missense_Mutation | c.955N>C | p.Ser319Pro | p.S319P | Q14152 | protein_coding | deleterious(0) | benign(0.237) | TCGA-BR-8680-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR | |
EIF3A | SNV | Missense_Mutation | c.2361G>C | p.Arg787Ser | p.R787S | Q14152 | protein_coding | deleterious(0) | benign(0.081) | TCGA-CG-4466-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
EIF3A | SNV | Missense_Mutation | rs762013834 | c.2806N>T | p.Arg936Trp | p.R936W | Q14152 | protein_coding | deleterious(0.01) | benign(0.186) | TCGA-FP-A4BE-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
EIF3A | SNV | Missense_Mutation | rs755084308 | c.1007N>T | p.Thr336Met | p.T336M | Q14152 | protein_coding | deleterious(0.03) | probably_damaging(0.996) | TCGA-FP-A4BE-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
EIF3A | SNV | Missense_Mutation | novel | c.3713N>A | p.Arg1238His | p.R1238H | Q14152 | protein_coding | tolerated_low_confidence(0.12) | benign(0.379) | TCGA-HF-A5NB-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | fluorouracil | SD |
EIF3A | SNV | Missense_Mutation | rs143903271 | c.4097G>A | p.Arg1366His | p.R1366H | Q14152 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.991) | TCGA-HU-A4GX-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | taxol | SD |
EIF3A | SNV | Missense_Mutation | novel | c.1573G>T | p.Ala525Ser | p.A525S | Q14152 | protein_coding | tolerated(0.66) | probably_damaging(0.985) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response | |
EIF3A | deletion | Frame_Shift_Del | novel | c.2556delN | p.Glu853LysfsTer320 | p.E853Kfs*320 | Q14152 | protein_coding | TCGA-CD-8533-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Chemotherapy | capecitabine | PD | ||
EIF3A | SNV | Missense_Mutation | c.3635A>T | p.Asp1212Val | p.D1212V | Q14152 | protein_coding | deleterious_low_confidence(0.04) | benign(0.151) | TCGA-H2-A421-01 | Thyroid | thyroid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8661 | EIF3A | NA | Platinum compounds | |||
8661 | EIF3A | NA | carboplatin | CARBOPLATIN | 23127338 | |
8661 | EIF3A | NA | cisplatin | CISPLATIN | 23127338 |
Page: 1 |